Key clinical point: Azacitidine plus enasidenib improved responses in newly diagnosed AML with isocitrate dehydrogenase 2 mutations, compared with azacitidine alone. However, OS did not improve.
Major finding: Median OS was 22 months in both arms (HR 0.99, 95% CI 0.52-1.87, P = .97).
Study details: Phase 2 open label trial with 101 subjects.
Disclosures: The work was funded by enasidenib marketer Celgene. The lead investigator is an adviser to, and receives research funding from, the company.
DiNardo CD et al. EHA Congress, abstract S139.